Human Immunodeficiency Virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection, solid organ transplantation, or other immunosuppressed state (for treatment phase)
Immunosuppressed status due to known human immunodeficiency virus (HIV) infection, severe uncontrolled diabetes, concurrent hematological malignancy, or other comorbidities
Has a diagnosis of immunodeficiency including subjects infected with human immunodeficiency virus (HIV)
Procurement: Patients with active human immunodeficiency virus (HIV) infection (can be pending at this time)
Human immunodeficiency virus (HIV) infection
Infection with human immunodeficiency virus (HIV)
Patients may not have diagnosed human immunodeficiency virus (HIV)
Human Immunodeficiency Virus infection at screening.
Human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV /)
Human immunodeficiency virus (HIV)
Human Immunodeficiency Virus (HIV) infection
Human immunodeficiency virus (HIV) infection.
Subjects must not have a confirmed human immunodeficiency virus (HIV) infection.
Human immunodeficiency virus (HIV) infection.
Active human immunodeficiency virus (HIV) infection
Uncontrolled human immunodeficiency virus (HIV) infection
Uncontrolled human immunodeficiency virus (HIV)
Participants that are cancer survivors or those with human immunodeficiency virus (HIV) will not be excluded from the study
Human immunodeficiency virus (HIV) infection
Documented human immunodeficiency virus (HIV)-infection
Infection with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Diagnosed immunodeficiency, eg, human immunodeficiency virus (HIV)
Patients with human immunodeficiency virus (HIV) are not permitted to enroll
Immunosuppressive disease or human immunodeficiency virus infection
Patients with human immunodeficiency virus (HIV) infection are excluded from the study
Human immunodeficiency virus (HIV) infection with CD count < 
Not be in an immunosuppressed state (e.g. human immunodeficiency virus [HIV], use of chronic steroids)
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Research participants who have confirmed human immunodeficiency virus (HIV) within  weeks of screening
Previous therapy with a human immunodeficiency virus (HIV) protease inhibitor
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
RECIPIENT: Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Patients must have an expected survival without treatment of >  days and must be free of major infection including human immunodeficiency virus (HIV)
DONOR: Infection with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV)+ serology
Human immunodeficiency virus (HIV) infection
Autoimmune disease requiring therapy, prior organ transplant, or human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Subjects cannot have an active immunodeficiency disorder, e.g. human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Confirmed human immunodeficiency virus (HIV) infection.
Active systemic infection requiring treatment, including any human immunodeficiency virus (HIV) infection or toxoplasmosis
No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies
Patients with human immunodeficiency virus (HIV) infection are ineligible
Human immunodeficiency virus (HIV) infection
Immunodeficiency states including human immunodeficiency virus (HIV) infection
DONOR: Infection with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection.
Human immunodeficiency virus (HIV)-infection
Infection with human immunodeficiency virus (HIV)
No human immunodeficiency virus (HIV) disease; patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies
Human immunodeficiency virus infection.
Human immunodeficiency virus (HIV) antibody
Patient Human Immunodeficiency Virus (HIV) infection
Human Immunodeficiency Virus (HIV) infection
No infection with human immunodeficiency virus (HIV)
Patients with active and uncontrolled human immunodeficiency virus (HIV) infection will be excluded; however, patients with well controlled HIV infection will be considered
Human immunodeficiency virus (HIV) infection
No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis
Documented human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV)
Uncontrolled human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection or immunodeficiency disorders, either primary or acquired
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
Anti-human immunodeficiency virus (HIV)  Antibody (alpha-HIV )
Infection with human immunodeficiency virus (HIV)
Patients with human immunodeficiency virus (HIV)
Human immunodeficiency virus infection
Human immunodeficiency virus (HIV) infection
Human Immunodeficiency Virus (HIV) infection
Human immunodeficiency virus (HIV) associated lymphoma
Evidence of human immunodeficiency virus (HIV) infection
Active cardiac disease and human immunodeficiency virus (HIV) infection
No uncontrolled infection\r\n* Note: Infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case-by-case basis
Human Immunodeficiency Virus (HIV) infection.
Patients with human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Patient has significant comorbidities (e.g., human immunodeficiency virus [HIV], transplant), or another illness that may require hospitalization
No uncontrolled infection\r\n* Note: infection is permitted if there is evidence of response to medication; eligibility of human immunodeficiency virus (HIV) infected patients will be determined on a case?by?case basis
Human immunodeficiency virus (HIV) infection
Uncontrolled human immunodeficiency virus (HIV), CD count < 
Patients with human immunodeficiency virus (HIV) are excluded
Presence of active infection including human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) infection
Patients who receive maraviroc for the treatment of human immunodeficiency virus (HIV) infection
Patients must be human immunodeficiency virus (HIV) non-reactive
Human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection
No human immunodeficiency virus (HIV) disease (patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies)
Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment
Patients with human immunodeficiency virus (HIV) infection
Human immunodeficiency virus (HIV) infection